Evidence map›Paper›PMID 37824640›Full record

ArticleScience (New York, N.Y.)2023

Probiotic-guided CAR-T cells for solid tumor targeting.

Rosa L Vincent, Candice R Gurbatri, Fangda Li, Ana Vardoshvili, Courtney Coker, Jongwon Im, Edward R Ballister, Mathieu Rouanne, Thomas Savage, Kenia de Los Santos-Alexis and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed, 2 pooled it
49.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 2 syntheses or guidelines pooled it, 217 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Engineering an arginine-nitric oxide circuit inTranslational cancer research · 2026
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Living Microbial Drugs.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  18. Review
  19. Review
  20. Review

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Rosa L Vincent *Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA.ORCID 0000-0003-0742-8977
Candice R Gurbatri *Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA.ORCID 0000-0002-1464-7089
Fangda LiDepartment of Microbiology and Immunology, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.
Ana VardoshviliDepartment of Biomedical Engineering, Columbia University, New York, NY 10027, USA.
Courtney CokerDepartment of Biomedical Engineering, Columbia University, New York, NY 10027, USA.ORCID 0000-0002-8779-133X
Jongwon ImDepartment of Biomedical Engineering, Columbia University, New York, NY 10027, USA.ORCID 0000-0002-3660-2770
Edward R BallisterDepartment of Biomedical Engineering, Columbia University, New York, NY 10027, USA.ORCID 0000-0002-4478-2513
Mathieu RouanneDepartment of Microbiology and Immunology, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.ORCID 0000-0003-2970-4821
Thomas SavageDepartment of Microbiology and Immunology, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.ORCID 0000-0002-6618-2973
Kenia de Los Santos-AlexisDepartment of Microbiology and Immunology, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.ORCID 0000-0002-3628-9796
Andrew RedentiDepartment of Biomedical Engineering, Columbia University, New York, NY 10027, USA.
Leonie BrockmannDepartment of Microbiology and Immunology, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.
Meghna KomaranchathDepartment of Biomedical Engineering, Columbia University, New York, NY 10027, USA.
Nicholas ArpaiaDepartment of Microbiology and Immunology, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.ORCID 0000-0002-0657-0528
Tal DaninoDepartment of Biomedical Engineering, Columbia University, New York, NY 10027, USA.ORCID 0000-0003-2713-7659
Columbia University · USColumbia University Irving Medical Center · US

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Probiotic guided CAR-T therapy (ProCARs) for breast cancerR01EB030352 · NIBIB · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DANINO, TAL · 2020 to 2023
$2.7M
NCATS NIH HHS UL1 TR001873NCI NIH HHS P30 CA013696NIBIB NIH HHS R01 EB030352
6 · The paper itself

Abstract

A major challenge facing tumor-antigen targeting therapies such as chimeric antigen receptor (CAR)-T cells is the identification of suitable targets that are specifically and uniformly expressed on heterogeneous solid tumors. By contrast, certain species of bacteria selectively colonize immune-privileged tumor cores and can be engineered as antigen-independent platforms for therapeutic delivery. To bridge these approaches, we developed a platform of probiotic-guided CAR-T cells (ProCARs), in which tumor-colonizing probiotics release synthetic targets that label tumor tissue for CAR-mediated lysis in situ. This system demonstrated CAR-T cell activation and antigen-agnostic cell lysis that was safe and effective in multiple xenograft and syngeneic models of human and mouse cancers. We further engineered multifunctional probiotics that co-release chemokines to enhance CAR-T cell recruitment and therapeutic response.

Indexed as

Breast NeoplasmsColorectal NeoplasmsEscherichia coliImmunotherapy, AdoptiveProbioticsReceptors, Chimeric AntigenAnimalsAntigens, NeoplasmCell EngineeringHumansLymphocyte ActivationMiceT-LymphocytesXenograft Model Antitumor AssaysAntigens, NeoplasmReceptors, Chimeric Antigen

Identifiers

PMID37824640
PMCPMC10915968
OpenAlexW4387568373

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.